Special Issue

Role of Next Generation Vaccines in Immunotherapeutics

Message from the Guest Editor

Vaccines have been instrumental in combating diseases, and next-generation vaccines represent a transformative leap forward in preventing infections and advancing immunotherapeutics. Next-generation vaccines encompass nucleic acid vaccines (DNA and RNA), viral vector vaccines, protein subunit vaccines, and recombinant vector vaccines. They offer several advantages over traditional vaccines, such as rapid development, stability, and the ability to elicit specific immune responses. Nucleic acid vaccines, particularly mRNA vaccines, gained global attention during the COVID-19 pandemic for their rapid development and high efficacy. Viral vector and protein subunit vaccines are also being explored for their potential to develop targeted and less reactive vaccines. Next-generation vaccines also show promise in treating chronic diseases, cancers, and autoimmune conditions. They can target specific tumor antigens in cancer immunotherapy and modulate immune responses in autoimmune diseases and allergies. We invite you to contribute a research or review article linking different components of the virus or vaccine to immune responses and clinical or preclinical data.

Guest Editor

Dr. Swayam Prakash
Institute for Immunology, School of Medicine, University of California Irvine, Irvine, CA 92697, USA

Deadline for manuscript submissions

30 September 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/201210

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI